Meta-Analysis of Novel Glucose-Lowering Agents in Patients With Type 2 Diabetes Mellitus Without Pre-existing Heart Failure

Meta-Analysis of Novel Glucose-Lowering Agents in Patients With Type 2 Diabetes Mellitus Without Pre-existing Heart Failure

[...]discrepancies in trial and patient characteristics could lead to possible clinical heterogeneity. [...]trials included in this meta-analysis often consist of patients with long-term T2DM, but patients in our study were followed up to a median of only 2.4 years. [...]SGLT2i were most effective i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2022-07, Vol.174, p.184-188
Hauptverfasser: Ahmed, Aymen, Shahid, Izza, Siddiqi, Ahmed Kamal, Ellahi, Aayat, Shurjeel, Qazi, Rashid, Ahmed Mustafa, Maniya, Talha
Format: Artikel
Sprache:eng
Schlagworte:
Clinical trials
Congestive heart failure
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Glucose
Heart failure
Heterogeneity
Meta-analysis
Patients
Population
Prevention
Stroke
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[...]discrepancies in trial and patient characteristics could lead to possible clinical heterogeneity. [...]trials included in this meta-analysis often consist of patients with long-term T2DM, but patients in our study were followed up to a median of only 2.4 years. [...]SGLT2i were most effective in reducing the incidence of HHF/CV death and HHF, whereas GLP-1 agonists reduced HHF/CV death but not HHF.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2022.04.001